Fosigotifator

Unknown / undisclosed

Phase 2/3topline reported

Evidence outlook · registrational

Topline reported 2025-01-06

No completed mid-stage readout is on record. The sponsor reported topline results on 2025-01-06 (HEALEY ALS Platform Trial Regimen F (NCT05740813) Phase 2/3 missed its primary endpoint). The announcement is listed under Regulatory events.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (2)
Other / comorbidity
NCT04297683 · Merit E. Cudkowicz, MD
2020-06-14 – 2028-08 · Amyotrophic Lateral Sclerosis
What this study did
NCT05740813 · Merit E. Cudkowicz, MD
2023-03-23 – 2024-10-03 · Amyotrophic Lateral Sclerosis
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT05757141 · Calico Life Sciences LLC
2023-03-13 – 2035-10 · Vanishing White Matter Disease
What this study did
Phase 1 (7)
Other / comorbidity
NCT07272525 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2024-11-14 – 2027-12-31 · Cree Leukoencephalopathy, Vanishing White Matter
What this study did
NCT06618118 · AbbVie
2024-10-23 – 2025-09-23 · Major Depressive Disorder (MDD)
What this study did
NCT04948645 · AbbVie
2021-09-22 – 2025-07-15 · ALS, Amyotrophic Lateral Sclerosis
What this study did
NCT06425003 · Calico Life Sciences LLC
2024-05-21 – 2024-07-12 · Healthy Volunteer
What this study did
NCT06310876 · Calico Life Sciences LLC
2024-03-14 – 2024-06-26 · Healthy
What this study did
NCT06145607 · Calico Life Sciences LLC
2023-12-19 – 2024-02-26 · Healthy
What this study did
NCT05763459 · Calico Life Sciences LLC
2023-03-24 – 2023-06-02 · Healthy
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT07300397 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2025-12-03 – 2029-01-03 · Cree Leukoencephalopathy
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Fosigotifator to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
July 2027 (1)
Phase 2/3Amyotrophic Lateral SclerosisActive not recruiting
Est. primary completion 2027-07 · NCT04297683 · CT.gov ↗
What to watch
November 2027 (2)
Phase 1/2Vanishing White Matter DiseaseRecruiting
Est. primary completion 2027-11 · NCT05757141 · CT.gov ↗
What to watch
Phase 1Cree Leukoencephalopathy, Vanishing White MatterActive not recruiting
Est. primary completion 2027-11-30 · NCT07272525 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
Early phase / not applicableCree LeukoencephalopathyActive not recruiting
Est. primary completion 2029-01-03 · NCT07300397 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 January 2025Topline resultHEALEY ALS Platform Trial Regimen F (NCT05740813) Phase 2/3 missed its primary endpoint
Calico Life Sciences LLC (Calico) · Source ↗